All right. Let us begin the conference. Greetings and welcome to the PetVivo Holdings Second Quarter Fiscal Year 2023 Financial Results Conference Call. I am John Dolan, the Chief Business Development Officer and General Counsel at PetVivo. Today’s call is being webcast and will be posted on the company’s website for playback. Before we begin, I would like to remind everyone that comments made during this conference call by PetVivo’s executives may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties. Any statement that refers to expectations, projections or other characterizations of future events, including financial projections or future market conditions, is a forward-looking statement. PetVivo’s actual future results could differ materially from those expressed in such forward-looking statements for any reason, including those listed in its SEC filings. PetVivo assumes no obligation to update any such forward-looking statements. PetVivo filed its earnings release and Form 10-Q with the SEC today, which provide a detailed overview of our financial results. These documents can be found on the SEC website and the Investor Relations section of our website. I would like to now turn the conference over to John Lai, the CEO and President of PetVivo. Please go ahead, John.

Thank you, John, and welcome. Joining me today is Bob Folkes, our Chief Financial Officer. I would like to begin by discussing some highlights from last quarter, and then Bob Folkes will discuss the financial results and conditions in greater detail. I will conclude by sharing some additional thoughts on our business strategy as key focus areas for fiscal 2023 before we open the line up for questions. Our key highlights for the second quarter of fiscal 2023 were reported revenues of $223,280 as compared to $4,977 in the second quarter of fiscal year 2022. Revenues for the second quarter included net revenues of $118,264 from shipments of Spryng to MWI, a subsidiary of AmerisourceBergen – our lead distributor of animal health products pursuant to the distribution and sales agreement with MWI dated June 17, 2022; expanded our national presence and have open accounts with veterinary clinics in 14 Southern states now. We’ve also added a 3 ml syringe as a new SKU. We are very pleased with the launch of Spryng with MWI. We have started training their sales team of over 400 territorial managers and are happy with the sell-through of the Spryng product into the market to the veterinary doctors. We will be attending the American Association of Equine Practitioners Annual Conference in November of 2022, and we’ll be coordinating sales efforts with MWI at this important meeting, which is the largest conference for veterinary equine practitioners. I would like to now turn the call over to Robert Folkes, our Chief Financial Officer, who will discuss our financial condition.

Thank you, John, and good afternoon, everyone. As John mentioned, the most significant event for the quarter was a total revenue of approximately $223,000, highlighted by the net revenue of $118,000 to MWI. At September 30, 2022, the company had $2.3 million in cash and working capital of $2.1 million. During the quarter, we increased our inventory to $305,000 in order to support our expected revenue growth for this current fiscal year. We continue to use the net proceeds from our initial public offering to expand our sales and marketing efforts and invest in clinical studies to gain acceptance and increase revenues from the sale of Spryng. So, now I will turn the call back over to John Lai.

Thank you, Bob. I would like to talk more about the business strategy and key focus areas for fiscal 2023. We’re in the process of generating a whole series of clinical evidence to support the equine and small animal market with MWI. John Dolan will go into a little more detail about these studies. We hired sales territorial managers to support the relationship with MWI and we’ll be adding more as the year goes on. We’re also exhibiting at multiple conferences to promote awareness of Spryng. The conference will also feature presentations from Dr. Joe Manning and Dr. Ann discussing the applications of Spryng. Additionally, on our Spryng Health website, we have a whole series of supporting videos showcasing various injections or the most common injections as an educational tool. We’re building this whole system of education to support MWI, and this will be crucial as we move forward in getting the product out into the market. We are, once again, getting really good traction in the marketplace. Now, I would like to turn the call over to John Dolan to provide an update on our clinical trials, which will be helpful in supporting our relationship with MWI. In addition, we expect that having more clinical data on the efficacy of Spryng will help us gain more acceptance from veterinary doctors.

Thank you, John. As John mentioned, clinical trials are incredibly important to our company. We have entered into a clinical trial services agreement with Colorado State University on November 5, 2020, in which we are evaluating the injection of Spryng on elbow-associated osteoarthritis in dogs. Unfortunately, due to COVID, there were some delays with this trial. We expect this study to be fully enrolled by the end of December 2022 and the data available in the fourth quarter of the fiscal year ending March 31, 2024. Additionally, we entered into a canine clinical study with Ethos Veterinary Health in May of 2022. This is a pilot study in which we are evaluating intra-articular injection of Spryng in dogs with stifle disease for initial product tolerance and efficacy. We expect the data for the first cohort of dogs to be available in or before March of 2023. Additionally, in October 2022, we completed enrollment in a canine tolerance study in which we are evaluating the intra-articular injection of Spryng in dogs for product safety. We expect to have this data available in the fourth quarter of the fiscal year ending March 31, 2023. Finally, in October 2023, we initiated a feline tolerance study in which we are evaluating intra-articular injection of Spryng in cats for product safety. We expect to have this data available in or before June of 2024. We expect to conduct additional clinical studies to support our relationship with MWI and gain vet acceptance of Spryng. Now, I’d like to turn it back over to John Lai.

Thank you, John. I would like to open the line for questions. John Dolan, can you explain to people how to ask questions, please?

Thank you, John. I would like to open the line for questions. John Dolan, can you explain to people how to ask questions, please?

We expect to have this data available in or before June of 2024. We anticipate conducting additional clinical studies to strengthen our relationship with MWI and gain veterinary acceptance of Spryng. Now, I’d like to turn it back over to John Lai. Thank you, John. I would like to open the line for questions. John Dolan, can you explain to people how to ask questions, please?

Very good. Thank you. I am not seeing any questions. Does anyone have a question?

Well, John, if we’re not seeing any questions, I’ll just make a closing comment and then we can end this call.

Very good.

So, regarding the AAEP, which is the American Association of Equine Practitioners, last year was a very big event for us, providing us with a whole series of vets that were trying our product, and we were able to get some good repeat orders from these veterinary doctors. This year, we expect it to be even larger. It’s a much bigger event, held in San Antonio. Also, if you saw the news release last Friday, or sometime this week, we talked about Dr. Joe Manning presenting some of the applications and successes we have seen using the product in the equine space for multiple applications. So, we’re quite excited about that, working with MWI. Moreover, on our Spryng Health website, Dr. Turner presents a whole series of videos that show how to use the product and the various applications. We also have a series of intra-articular injections for the small animal side listed on that website. This website is more designed for veterinary professionals. That’s some of the supporting data we discussed on the previous call or the previous quarter that we would be developing, which will be instrumental in helping MWI educate the vets as well as assisting them in securing orders for various applications. We have multiple catalysts coming up. We completed the Ethos study at the end of October. Given the time it takes to get it published, we’re looking at getting it out in February or March of 2023, which will coincide with the new season of major trade shows and events where we can present a lot of this data. That’s the plan, which should help us accelerate the small animal adoption at a much faster rate. So with that, and if there are no more questions, that will conclude our call.